Purinergic Signal
Purinergic Signalling
1573-9538
1573-9546
Springer Netherlands
Dordrecht


2245998
18368530
9078
10.1007/s11302-007-9078-7
Review


P2 receptors in cardiovascular regulation and disease

Erlinge
David

+46-46-172597
+46-46-157857
david.erlinge@med.lu.se

1

Burnstock
Geoffrey

+44-020-78302948
+44-020-78302949
g.burnstock@ucl.ac.uk

2

1
Department of Cardiology, Lund University Hospital, 22185 Lund, Sweden 
2
Autonomic Neuroscience Centre, Royal Free and University College Medical School, Rowland Hill Street, London, NW3 2PF UK 

21
9
2007

3
2008

4
1
1
20
3
5
2007

22
8
2007


© Springer Science + Business Media B.V. 2007

The role of ATP as an extracellular signalling molecule is now well established and evidence is accumulating that ATP and other nucleotides (ADP, UTP and UDP) play important roles in cardiovascular physiology and pathophysiology, acting via P2X (ion channel) and P2Y (G protein-coupled) receptors. In this article we consider the dual role of ATP in regulation of vascular tone, released as a cotransmitter from sympathetic nerves or released in the vascular lumen in response to changes in blood flow and hypoxia. Further, purinergic long-term trophic and inflammatory signalling is described in cell proliferation, differentiation, migration and death in angiogenesis, vascular remodelling, restenosis and atherosclerosis. The effects on haemostasis and cardiac regulation is reviewed. The involvement of ATP in vascular diseases such as thrombosis, hypertension and diabetes will also be discussed, as well as various heart conditions. The purinergic system may be of similar importance as the sympathetic and renin-angiotensin-aldosterone systems in cardiovascular regulation and pathophysiology. The extracellular nucleotides and their cardiovascular P2 receptors are now entering the phase of clinical development.

Keywords
ATP
Cardiovascular
Heart
Pathophysiology
Purine
Pyrimidine
P2X
P2Y
Receptor

issue-copyright-statement
© Springer Science+Business Media B.V. 2008




Introduction
1
2
3
4
5
6
1
7
8
9
15
15
19
Table 1
Receptor classification, intracellular signalling, ligands and selective agonists and antagonists

P2 subtype
I.c. signalling
Ligand
Selective agonist
Selective antagonist
Non-selective antagonist


1

↑IP3
ADP (ATP)
MRS2365
MRS 2179, MRS2500


2

↑IP3
UTP = ATP
MRS2498, UTPγS, INS3717

Suramin > RB2

4

↑IP3
UTP (=ATP in rodents)
UTPγS, INS3717
–
RB2 > Suramin

6

↑IP3
UDP
MRS2666, MRS2633, UDPβS
MRS2578


11

↑IP3, ↑cAMP
ATP
AR-C67085MX, NF546
NF157
Suramin > RB2

12

↓cAMP
ADP
–
Clopidogrel, prasugrel, AZD6140, INS50589, AR-C9931 (cangrelor)


13

↓cAMP
ADP
–
MRS2211


14

IP3
UDP-glucose, UDP-galactose
UDP-glucose, UDP-galactose
–


1

Positive ion channel
ATP
α,β-mATP
NF023, NF449
5
I

2

Positive ion channel
ATP
–
NF770
Suramin, isoPPADS, RB2

3

Positive ion channel
ATP
α,β-mATP
A317491, NF110
Suramin

4

Positive ion channel
ATP
Ivermectin potentiates
–
TNP-ATP

5

Positive ion channel
ATP
–
–
Suramin, PPADS

6

Positive ion channel
ATP
–
–
–

7

Positive ion channel
ATP
–
KN62, KN04, MRS2427
Coomassie brilliant blue G

Ectonucleotidase


Apyrase, human SolCD39
ARC67156






2
]. In preparation of this review more than 2,700 references on P2 receptors and cardiovascular regulation were found in PubMed. Among the 15 receptor subtypes, one is the target for one of the most widely used medical drugs—the platelet inhibitor clopidogrel (Plavix). As will be reviewed here, several of the other 15 receptors are promising drug targets to prevent cardiovascular disease.

Regulation of vascular tone
20
21
22
23
24
].
Neuronal regulation of vascular tone
11
25
26
27
28
1
25
1
29
30
1
2
1
31
32
1
32
33
Fig. 1
RBC
NO
EDHF
Pgl
VSMC
Ado
CGRP
SP
 substance P




1
34
35
36
37
], suggesting that ATP and UTP may mediate this important physiological mechanism.
38
1
39
40
1
41
2
6
42
42
43
44
6
6
45
1
6
44
].
12
46
12
46
12
46
].
1
1
2
6
12
1
2
Table 2
P2 receptor expression in the cardiovascular system

P2 subtype
Endothelium
VSMC
Heart
Platelets
Red blood cells
Inflammatory cells
Perivascular sensory nerves
Perivascular sympathetic nerves


1

High
–
–
High
(Turkey)

Medium
Medium (neg. feedback)

2

High
High
High
–
–
High
Low
Possible

4

–
Possible
–
–
–




6

Medium
Medium
High
–
–




11

Possible
–
High
–
–
High



12

–
Medium
–
High
–
Low



13

–
–
–
–
High
Low



14

–
–
–
–
–




1

–
High
Medium
High
–
Medium



2

–
–
–
–
–

High
Medium (pos. feedback)

3

–
–
–
–
–

High


4

High
–
Low
–
–
High



5

–
–
–
–
–




6

–
–
–
–
–




7

–
Possible
–
–
Low
High





VSMC
 vascular smooth muscle cell




Endothelial regulation
47
1
5
48
50
51
], indicating an important role for EDHF in P2 receptor-mediated vasodilatation in man.
1
11
2
6
40
52
4
53
]. UTP and ATP are equipotent as vasodilators when infused in the human forearm circulation, indicating a role for both purinergic and pyrimidinergic receptors.
1
4
40
54
4
2+
55
56
4
57
4
57
].
8
58
59
].
7
60
2A
61
62
1
63
63
2
4
1
2A
 receptors on smooth muscle cells.

Red blood cells as regulators of vascular tone
37
64
66
67
69
37
64
3
2
70
2
64
71
72
2
2
Table 3
Release of purines and pyrimidines in the cardiovascular system

Source
Endothelium
VSMC
Heart
Platelets
Red blood cells
Inflammatory cells
Vascular nerves


Stimuli
Shear stress, hypoxia, high glucose
High glucose, hypoxia
Hypoxia
Collagen, thromboxane, other platelet activators
Hypoxia, adrenaline, deformation
Infl. activators
Sympathetic nerves, sensory nerve collaterals

Mechanism
Vesicular
Unknown
Unknown
Vesicular
Unknown
Unknown or vesicular
Vesicular

Nucleotide
ATP, UTP
ATP, UTP
ATP, UTP
ADP > ATP
ATP
ATP
ATP

Target
Endothelium VSMC
VSMC
Cardiomyocytes, blood vessels, intrinsic cardiac neurons
Platelets; endothelium or VSMC
Endothelium
VSMC, endothelium
VSMC

Degradation
NTPDase1
NTPDase2, NTPDase1
NTPDase1
NTPDase1
NTPDase1
NTPDase1
NTPDase1 (co-released)



Stimuli
Mechanism
Target
Degradation
VSMC
 vascular smooth muscle cell



13
73
74
]. NO is then scavenged by haemoglobin.
75
7
76
77
Plasmodium
78
].
79
]. Erythrocytes do not form gap junctions, instead pannexin-1 forms a mechanosensitive ATP-permeable channel that mediates osmotically induced ATP release.

Hypertension
31
32
].
80
81
82
1
2
83
84
85
]. Thus, animal models of hypertension reveal several alterations in purinergic signalling that may contribute to the development of hypertension.
4
5
6
86
1
2
5
6
87
4
88
1
2
88
].
4
4
57
4
89
4
 receptors may be important for blood pressure regulation.
1
2
6
 receptor antagonists in the treatment of hypertension.

Pulmonary hypertension
90
69
91
92
]. Again, the balance between endothelial versus smooth muscle stimulation by ATP may regulate blood pressure in different directions and we are far from a full understanding of the role of the purinergic system in pulmonary hypertension.

Migraine and vascular pain
6
1D
93
94
3
95
3
96
97
Lancet
3
26
].


Atherosclerosis
98
2
99
100
101
Fig. 2
EC
VSCM
IL
MCP-1
ICAM-1
TSP
IDO
 indoleamine 2,3-dioxygenase




Atherosclerosis—P2 receptor-mediated effects on inflammatory cells
102
98
].
14
103
14
7
2
11
7
104
105
7
106
107
L
108
7
109
7
2
110
2
111
1
112
]. Whether this is due to platelet inhibition, endothelial or an inflammatory mechanism requires further studies.
11
113
11
114
115
].
11
116
11
11
98
11
 receptor is important in the development of atherosclerosis via modulation of inflammation either via effects on T lymphocytes or macrophage cells.

Proinflammatory effects on the endothelium
117
118
2
119
2
120
121
].
2
).


Restenosis and vascular smooth muscle cell proliferative disease
122
25
123
].
12
123
125
2
123
6
124
126
127
123
124
12
128
129
125
130
6
2
127
].
12
13
124
131
2
2
132
133
2
6
134
121
135
136
134
137
].
Diabetic microvascular disease
138
139
].
140
].
141
142
143
2
6
143
].
2
).


Vascular remodelling and angiogenesis
Vascular remodelling
13
2+
1
144
2
1
145
145
2
146
147
2
148
149
150
1
2
6
151
4
57
].

Angiogenesis
7
60
13
152
153
154
155
156
].

Varicose veins
7
157
1
2
1
158
151
].


Heart
3
7
60
159
160
60
161
].
Inotropy
60
162
165
3
2
162
164
167
4
168
].
3
169
1
60
170
171
60
11
s
60
172
174
11
161
175
].
164
166
176
177
161
2
4
161
2
6
161
3
-mediated signalling.
2
6
11
3
60
160
Fig. 3
a
b
c
NTPDase
 nucleoside triphosphate diphosphohydrolase





Myocardial infarction
60
60
178
161
179
180
] that could represent a compensatory mechanism against increased nucleotide levels during chronic ischaemia.
181
].
11
116
11
 receptor plays an important role in cardiovascular biology and in inflammatory disease (see above), causing myocardial infarction via a proinflammatory effect. However, increased inotropic effects may also contribute.
182
3
163
183
60
161
184
185
178
186
3
).

Congestive heart failure
187
11
1
169
6
188
1
189
].
4
190
11
11
2
6
 receptors stimulating the same intracellular pathways as angiotensin II. Synthetic agonists could thus be used as inotropic agents during circulatory shock and antagonists may have effects similar to angiotensin II receptor blockers, being beneficial in the treatment of hypertension and congestive heart failure.

Chronotropy and arrhythmia
191
60
1
192
]. However, so far no firm evidence exists of an important role for P2 receptors for chronotropy or arrhythmia.


Platelets and coagulation
Platelets
193
194
196
12
1
1
197
198
4
12
12
199
1
200
202
12
2
1
12
200
203
Fig. 4
t-PA
PAI-1
Ado
 adenosine




1
1
1
204
205
].
206
1
58
207
208
209
210
1
).
12
12
46
].

Coagulation
51
211
4
212
]. Thus, P2 receptors are involved at several stages of haemostasis, which is important for the development of atherosclerosis and thrombotic occlusions leading to myocardial infarction and stroke.

Clinical importance of P2 receptor-mediated regulation of platelets
12
 receptor resulting in non-competitive antagonism.
213
213
214
215
12
12
 receptor antagonists, such as prasugrel and AZD6140, have a stronger more consistent effect and are currently being studied in major clinical trials (TRITON and PLATO).


Clinical importance of purinergic signalling in cardiovascular disease: future directions
4
12
12
1
1
1
1
Table 4
Cardiovascular disease targets

Receptor target
Agonist/antagonist activity of therapeutic drug
Disease


Vascular smooth muscle cell

2

Antagonist
Hypertension, restenosis, diabetic microvascular disease, subarachnoidal bleeding

6

Antagonist
Hypertension, restenosis, diabetic microvascular disease, subarachnoidal bleeding

12

Antagonist
Hypertension, vasospasm

1

Antagonist
Hypertension, migraine, subarachnoidal bleeding

6

Agonist
Migraine

SolNTPDase1
Ectonucleotidase
Restenosis, xenograft rejection

Endothelial cell

2

Antagonist
Atherosclerosis, inflammation

4

Antagonist
Vascular remodelling (cancer?), preeclampsia

Heart

2

Antagonist
Congestive heart failure

6

Antagonist
Congestive heart failure

11

Antagonist
Congestive heart failure, myocardial infarction

2

Agonist
Shock, reduced cardiac output, cardiac protection

6

Agonist
Shock, reduced cardiac output

11

Agonist
Shock, reduced cardiac output

SolNTPDase1
Ectonucleotidase
Heart transplantation, myocardial infarction

Inflammatory cells

2

Antagonist
Atherosclerosis

11

Antagonist
Atherosclerosis

7

Antagonist
Atherosclerosis

Platelets

1

Antagonist
Myocardial infarction, stroke, peripheral artery disease

12

Antagonist
Myocardial infarction, stroke, peripheral artery disease

1

Antagonist
Myocardial infarction, stroke, peripheral artery disease

SolNTPDase1
Ectonucleotidase
Myocardial infarction, stroke, peripheral artery disease

Red blood cell

13

Antagonist
Improved peripheral circulation

7

Antagonist
Shock

Perivascular nociceptive sensory nerves

1

Agonist
Migraine, vascular pain

3

Antagonist
Migraine, vascular pain

Perivascular sympathetic nerves

1

Agonist
Hypertension

2

Antagonist
Hypertension



The table presents possible targets for the development of new pharmaceutical compounds for the treatment of cardiovascular diseases



2
6
 receptors, are potent stimulators of inflammation, VSMC proliferation and migration. Antagonists to these receptors may be explored to protect against atherosclerosis, restenosis after balloon angioplasty, chronic transplant rejection and diabetic microvascular disease.
1
2
6
12
2
6
11
11
 receptors could be considered as a prognostic marker to identify patients at risk of myocardial infarction and drugs aimed at the receptor could be explored to prevent myocardial infarction.
3
19
26
].


References
1.
Drury
A

Szent-Györgyi
A


The physiological activity of adenine compounds with special reference to their action upon the mammalian heart
J Physiol
1929
68
213
237

16994064


2.
Burnstock
G


Straub
RW


A basis for distinguishing two types of purinergic receptor
Cell membrane receptors for drugs and hormones: a multidisciplinary approach
1978
New York
Raven
107
118

Burnstock G (1978) A basis for distinguishing two types of purinergic receptor. In: Straub RW (ed) Cell membrane receptors for drugs and hormones: a multidisciplinary approach. Raven, New York, pp 107–118 

3.
Burnstock
G


Purinergic nerves
Pharmacol Rev
1972
24
509
581

4404211


4.
Burnstock
G


The past, present and future of purine nucleotides as signalling molecules
Neuropharmacology
1997
36
1127
1139

9364468


5.
Ralevic
V

Burnstock
G


Receptors for purines and pyrimidines
Pharmacol Rev
1998
50
413
492

9755289


6.
Burnstock
G


Physiology and pathophysiology of purinergic neurotransmission
Physiol Rev
2007
87
659
797

17429044


7.
Gordon
JL


Extracellular ATP: effects, sources and fate
Biochem J
1986
233
309
319

3006665


8.
Zimmermann
H


Ectonucleotidases in the nervous system
Novartis Found Symp
2006
276
113
128

16805426


9.
Burnstock
G

Kennedy
C


A dual function for adenosine 5′-triphosphate in the regulation of vascular tone. Excitatory cotransmitter with noradrenaline from perivascular nerves and locally released inhibitory intravascular agent
Circ Res
1986
58
319
330

3013455


10.
Olsson
RA

Pearson
JD


Cardiovascular purinoceptors
Physiol Rev
1990
70
761
845

2194223


11.
Ralevic
V

Burnstock
G


Roles of P2-purinoceptors in the cardiovascular system
Circulation
1991
84
1
14

1647896


12.
Erlinge
D


Extracellular ATP: a growth factor for vascular smooth muscle cells
Gen Pharmacol
1998
31
1
8

9595270


13.
Burnstock
G


Purinergic signalling and vascular cell proliferation and death
Arterioscler Thromb Vasc Biol
2002
22
364
373

11884276


14.
Virgilio
F

Solini
A


P2 receptors: new potential players in atherosclerosis
Br J Pharmacol
2002
135
831
842

11861311


15.
Gachet
C


Regulation of platelet functions by P2 receptors
Annu Rev Pharmacol Toxicol
2006
46
277
300

16402906


16.
Agteresch
HJ

Dagnelie
PC

Berg
JW



Adenosine triphosphate: established and potential clinical applications
Drugs
1999
58
211
232

10473017


17.
Ralevic
V

Burnstock
G


Involvement of purinergic signaling in cardiovascular diseases
Drug News Perspect
2003
16
133
140

12819811


18.
Atkinson
B

Dwyer
K

Enjyoji
K



Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets
Blood Cells Mol Dis
2006
36
217
222

16476557


19.
Burnstock
G


Pathophysiology and therapeutic potential of purinergic signaling
Pharmacol Rev
2006
58
58
86

16507883


20.
Burnstock
G


Do some nerve cells release more than one transmitter?
Neuroscience
1976
1
239
248

11370511


21.
Burnstock
G


Sympathetic purinergic transmission in small blood vessels
Trends Pharmacol Sci
1988
9
116
117

2907697


22.
Burnstock
G


Local control of blood pressure by purines
Blood Vessels
1987
24
156
160

3036284


23.
Burnstock
G


Vanhoutte
PM


Local purinergic regulation of blood pressure (The First John T. Shepherd Lecture)
Vasodilatation: vascular smooth muscle, peptides, autonomic nerves, and endothelium
1988
New York
Raven
1
14

Burnstock G (1988) Local purinergic regulation of blood pressure (The First John T. Shepherd Lecture). In: Vanhoutte PM (ed) Vasodilatation: vascular smooth muscle, peptides, autonomic nerves, and endothelium. Raven, New York, pp 1–14 

24.
Burnstock
G


Local mechanisms of blood flow control by perivascular nerves and endothelium
J Hypertens Suppl
1990
8
S95
S106

1982771


25.
Burnstock
G


Noradrenaline and ATP as cotransmitters in sympathetic nerves
Neurochem Int
1990
17
357
368

Burnstock G (1990) Noradrenaline and ATP as cotransmitters in sympathetic nerves. Neurochem Int 17:357–368 

26.
Burnstock
G


A unifying purinergic hypothesis for the initiation of pain
Lancet
1996
347
1604
1605

8667873


27.
Burnstock
G


Edvinsson
L

Uddman
R


Introduction: changing face of autonomic and sensory nerves in the circulation
Vascular innervation and receptor mechanisms: new perspectives
1993
New York
Academic
1
22

Burnstock G (1993) Introduction: changing face of autonomic and sensory nerves in the circulation. In: Edvinsson L, Uddman R (eds) Vascular innervation and receptor mechanisms: new perspectives. Academic, New York, pp 1–22 

28.
Rubino
A

Burnstock
G


Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function
Cardiovasc Res
1996
31
467
479

8689638


29.
Vial
C

Evans
RJ


1
6
-like receptor in arteries
Mol Pharmacol
2002
62
1438
1445

12435812


30.
Ramme
D

Regenold
JT

Starke
K



Identification of the neuroeffector transmitter in jejunal branches of the rabbit mesenteric artery
Naunyn Schmiedebergs Arch Pharmacol
1987
336
267
273

2891041


31.
Chan
CM

Unwin
RJ

Bardini
M



1
 purinoceptors by autoradiography and immunohistochemistry in rat kidneys
Am J Physiol
1998
274
F799
F804

9575906


32.
Inscho
EW

Cook
AK

Imig
JD



1
 knockout mice
Acta Physiol Scand
2004
181
445
453

15283757


33.
Inscho
EW

Cook
AK

Imig
JD



1
 receptors in renal microvascular autoregulatory behavior
J Clin Invest
2003
112
1895
1905

14679185


34.
Boehm
S

Huck
S


Receptors controlling transmitter release from sympathetic neurons in vitro
Prog Neurobiol
1997
51
225
242

9089789


35.
Cunha
R


Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors
Neurochem Int
2001
38
107
125

11137880


36.
Todorov
LD

Mihaylova-Todorova
S

Westfall
TD



Neuronal release of soluble nucleotidases and their role in neurotransmitter inactivation
Nature
1997
387
76
79

9139824


37.
Rosenmeier
JB

Hansen
J

Gonzalez-Alonso
J


Circulating ATP-induced vasodilatation overrides sympathetic vasoconstrictor activity in human skeletal muscle
J Physiol
2004
558
351
365

15155791


38.
Burnstock
G

Kennedy
C


Is there a basis for distinguishing two types of P2-purinoceptor?
Gen Pharmacol
1985
16
433
440

2996968


39.
Lewis
CJ

Evans
RJ


Comparison of P2X receptors in rat mesenteric, basilar and septal (coronary) arteries
J Auton Nerv Syst
2000
81
69
74

10869703


40.
Wang
L

Karlsson
L

Moses
S



P2 receptor expression profiles in human vascular smooth muscle and endothelial cells
J Cardiovasc Pharmacol
2002
40
841
853

12451317


41.
Kügelgen
I

Haussinger
D

Starke
K


Evidence for a vasoconstriction-mediating receptor for UTP, distinct from the P2 purinoceptor, in rabbit ear artery
Naunyn Schmiedebergs Arch Pharmacol
1987
336
556
560

3437923


42.
Malmsjö
M

Adner
M

Harden
TK



The stable pyrimidines UDPβS and UTPγS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery
Br J Pharmacol
2000
131
51
56

10960068


43.
Sévigny J et al (2006) Co-ordinated regulation of P2-receptor signaling by membrane bound NTPDases. Purinergic Signalling 2:53

44.
Borna
C

Wang
L

Gudbjartsson
T



Contractions in human coronary bypass vessels stimulated by extracellular nucleotides
Ann Thorac Surg
2003
76
50
57

12842512


45.
Brinson
AE

Harden
TK


4
6
4
 receptor
J Biol Chem
2001
276
11939
11948

11114308


46.
Wihlborg
AK

Wang
L

Braun
OO



12
 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels
Arterioscler Thromb Vasc Biol
2004
24
1810
1815

15308557


47.
Burnstock
G


Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction
J Anat
1999
194
335
342

10386771


48.
Malmsjö
M

Edvinsson
L

Erlinge
D


P2U-receptor mediated endothelium-dependent but nitric oxide-independent vascular relaxation
Br J Pharmacol
1998
123
719
729

9517392


49.
Malmsjö
M

Erlinge
D

Högestätt
ED



Endothelial P2Y receptors induce hyperpolarisation of vascular smooth muscle by release of endothelium-derived hyperpolarising factor
Eur J Pharmacol
1999
364
169
173

9932720


50.
Mistry
H

Gitlin
JM

Mitchell
JA



Endothelium-dependent relaxation and endothelial hyperpolarization by P2Y receptor agonists in rat-isolated mesenteric artery
Br J Pharmacol
2003
139
661
671

12788826


51.
Hrafnkelsdottir
T

Erlinge
D

Jern
S


Extracellular nucleotides ATP and UTP induce a marked acute release of tissue-type plasminogen activator in vivo in man
Thromb Haemost
2001
85
875
881

11372682


52.
Wihlborg
AK

Malmsjö
M

Eyjolfsson
A



Extracellular nucleotides induce vasodilatation in human arteries via prostaglandins, nitric oxide and endothelium-derived hyperpolarising factor
Br J Pharmacol
2003
138
1451
1458

12721100


53.
Guns
PJ

Korda
A

Crauwels
HM



Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta
Br J Pharmacol
2005
146
288
295

15997227


54.
Yamamoto
K

Korenaga
R

Kamiya
A



4
 receptors mediate ATP-induced calcium influx in human vascular endothelial cells
Am J Physiol Heart Circ Physiol
2000
279
H285
H292

10899068


55.
Yamamoto
K

Korenaga
R

Kamiya
A



2+
4
 purinoceptors
Circ Res
2000
87
385
391

10969036


56.
Bodin
P

Bailey
D

Burnstock
G


Increased flow-induced ATP release from isolated vascular endothelial cells but not smooth muscle cells
Br J Pharmacol
1991
103
1203
1205

1652343


57.
Yamamoto
K

Sokabe
T

Matsumoto
T



4
-deficient mice
Nat Med
2006
12
133
137

16327800


58.
Kaczmarek
E

Koziak
K

Sévigny
J



Identification and characterization of CD39/vascular ATP diphosphohydrolase
J Biol Chem
1996
271
33116
33122

8955160


59.
Yegutkin
G

Bodin
P

Burnstock
G


Effect of shear stress on the release of soluble ecto-enzymes ATPase and 5’-nucleotidase along with endogenous ATP from vascular endothelial cells
Br J Pharmacol
2000
129
921
926

10696091


60.
Vassort
G


Adenosine 5’-triphosphate: a P2-purinergic agonist in the myocardium
Physiol Rev
2001
81
767
806

11274344


61.
Saito
D

Steinhart
CR

Nixon
DC



Intracoronary adenosine deaminase reduces canine myocardial reactive hyperemia
Circ Res
1981
49
1262
1267

7307243


62.
Zatta
AJ

Headrick
JP


Mediators of coronary reactive hyperaemia in isolated mouse heart
Br J Pharmacol
2005
144
576
587

15655499


63.
Olivecrona
GK



1
 mediates early reactive hyperemia in vivo in pigs
Purinergic Signalling
2006
1
59
64

Olivecrona GK et al (2006) Coronary artery reperfusion: the ADP receptor P2Y1 mediates early reactive hyperemia in vivo in pigs. Purinergic Signalling 1:59–64 

64.
Ellsworth
ML

Forrester
T

Ellis
CG



The erythrocyte as a regulator of vascular tone
Am J Physiol
1995
269
H2155
H2161

8594927


65.
McMahon
TJ

Moon
RE

Luschinger
BP



Nitric oxide in the human respiratory cycle
Nat Med
2002
8
711
717

12042776


66.
Cosby
K

Partovi
KS

Crawford
JH



Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation
Nat Med
2003
9
1498
1505

14595407


67.
Bergfeld
GR

Forrester
T


Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia
Cardiovasc Res
1992
26
40
47

1325292


68.
Sprague
RS


Participation of cAMP in a signal-transduction pathway relating erythrocyte deformation to ATP release
Am J Physiol Cell Physiol
2001
281
C1158
C1164

11546651


69.
Sprague
RS

Stephenson
AH

Ellsworth
ML



Impaired release of ATP from red blood cells of humans with primary pulmonary hypertension
Exp Biol Med (Maywood)
2001
226
434
439

11393171


70.
Dietrich
HH

Ellsworth
ML

Sprague
RS



Red blood cell regulation of microvascular tone through adenosine triphosphate
Am J Physiol Heart Circ Physiol
2000
278
H1294
H1298

10749727


71.
Gonzalez-Alonso
J

Olsen
DB

Saltin
B


Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery: role of circulating ATP
Circ Res
2002
91
1046
1055

12456491


72.
Farias
M

Gorman
MW

Savage
MV



Plasma ATP during exercise: possible role in regulation of coronary blood flow
Am J Physiol Heart Circ Physiol
2005
288
H1586
H1590

15563530


73.
Wang
L

Olivecrona
G

Götberg
M



13
 receptors is a negative feedback pathway for ATP release from human red blood cells
Circ Res
2005
96
189
196

15604418


74.
Olearczyk
JJ

Ellsworth
ML

Stephenson
AH



Nitric oxide inhibits ATP release from erythrocytes
J Pharmacol Exp Ther
2004
309
1079
1084

14766946


75.
Trams
EJ

Kauffman
H

Burnstock
G


A proposal for the role of ecto-enzymes and adenylates in traumatic shock
J Theor Biol
1980
87
609
621

6454030


76.
Sluyter
R

Shemon
AN

Barden
JA



7
 receptor
J Biol Chem
2004
279
44749
44755

15304508


77.
Bodin
P

Burnstock
G


ATP-stimulated release of ATP by human endothelial cells
J Cardiovasc Pharmacol
1996
27
872
875

8761855


78.
Tanneur
V

Duranton
C

Brand
VB


Purinoceptors are involved in the induction of an osmolyte permeability in malaria-infected and oxidized human erythrocytes
FASEB J
2006
20
133
135

16267125


79.
Locovei
S

Bao
L

Dahl
G


Pannexin 1 in erythrocytes: function without a gap
Proc Natl Acad Sci USA
2006
103
7655
7659

16682648


80.
Vidal
M

Hicks
PE

Langer
SZ


Differential effects of α-β-methylene ATP on responses to nerve stimulation in SHR and WKY tail arteries
Naunyn Schmiedebergs Arch Pharmacol
1986
332
384
390

3755503


81.
Brock
JA

Helden
DF


Enhanced excitatory junction potentials in mesenteric arteries from spontaneously hypertensive rats
Pflugers Arch
1995
430
901
908

8594542


82.
Fernandez
O

Wangensteen
R

Osuna
A



2
-purinoceptor activation in spontaneously hypertensive rats
Pharmacology
2000
60
47
50

10629443


83.
Galligan
JJ

Hess
MC

Miller
SB



Differential localization of P2 receptor subtypes in mesenteric arteries and veins of normotensive and hypertensive rats
J Pharmacol Exp Ther
2001
296
478
485

11160634


84.
Yang
D

Gluais
P

Zhang
JN



Endothelium-dependent contractions to acetylcholine, ATP and the calcium ionophore A 23187 in aortas from spontaneously hypertensive and normotensive rats
Fundam Clin Pharmacol
2004
18
321
326

15147283


85.
Vonend
O

Turner
CM

Chan
CM



Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models
Kidney Int
2004
66
157
166

15200422


86.
Schluter
H

Offers
E

Brüggemann
G



Diadenosine phosphates and the physiological control of blood pressure
Nature
1994
367
186
188

8114917


87.
Hollah
P

Hausberg
M

Kosch
M



A novel assay for determination of diadenosine polyphosphates in human platelets: studies in normotensive subjects and in patients with essential hypertension
J Hypertens
2001
19
237
245

11212966


88.
Jankowski
V

Tölle
M

Vanholder
R



Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor
Nat Med
2005
11
223
227

15665829


89.
Roberts
VH

Webster
RP

Brockman
DE



4
 purinergic receptor subtype in the human placenta are altered in preeclampsia
Placenta
2006
28
270
277

16793133


90.
Sprague
RS

Olearczyk
JJ

Spence
DM



Extracellular ATP signaling in the rabbit lung: erythrocytes as determinants of vascular resistance
Am J Physiol Heart Circ Physiol
2003
285
H693
H700

12689860


91.
Greenberg
B

Rhoden
K

Barnes
PJ


Endothelium-dependent relaxation of human pulmonary arteries
Am J Physiol
1987
252
H434
H438

3812755


92.
Zhang
S

Remillard
CV

Fantozzi
I



ATP-induced mitogenesis is mediated by cyclic AMP response element-binding protein-enhanced TRPC4 expression and activity in human pulmonary artery smooth muscle cells
Am J Physiol Cell Physiol
2004
287
C1192
C1201

15229105


93.
Malmsjö
M

Hou
M

Pendergast
W



6
 receptor mediated contractions in human cerebral arteries
BMC Pharmacol
2003
3
4

12737633


94.
Burnstock
G


The role of adenosine triphosphate in migraine
Biomed Pharmacother
1989
43
727
736

2701287


95.
Waeber
C

Moskowitz
MA


Therapeutic implications of central and peripheral neurologic mechanisms in migraine
Neurology
2003
61
S9
S20

14581653


96.
Fabbretti
E

D’Arco
M

Fabbro
A



3
 receptors of trigeminal sensory neurons by calcitonin gene-related peptide
J Neurosci
2006
26
6163
6171

16763024


97.
Peroutka
SJ


Migraine: a chronic sympathetic nervous system disorder
Headache
2004
44
53
64

14979884


98.
Hansson
GK


Inflammation, atherosclerosis, and coronary artery disease
N Engl J Med
2005
352
1685
1695

15843671


99.
Hashimoto
M

Shinozuka
K

Shahdat
HM



Antihypertensive effect of all-cis-5,8,11,14,17-icosapentaenoate of aged rats is associated with an increase in the release of ATP from the caudal artery
J Vasc Res
1998
35
55
62

9482696


100.
Hashimoto
M

Shinozuka
K

Tanabe
Y



Long-term supplementation with a high cholesterol diet decreases the release of ATP from the caudal artery in aged rats
Life Sci
1998
63
1879
1885

9825766


101.
Karoon
P

Burnstock
G


Reduced sympathetic noradrenergic neurotransmission in the tail artery of Donryu rats fed with high cholesterol-supplemented diet
Br J Pharmacol
1998
123
1016
1021

9535033


102.
Virgilio
F

Chiozzi
P

Ferrari
D



Nucleotide receptors: an emerging family of regulatory molecules in blood cells
Blood
2001
97
587
600

11157473


103.
Wang
L

Jacobsen
SE

Bengtsson
A



P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells
BMC Immunol
2004
5
16

15291969


104.
Baricordi
OR

Ferrari
D

 Melchiorri
L



An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes
Blood
1996
87
682
690

8555491


105.
Kawamura
H

Aswad
F

Minagawa
M



7
 receptor-dependent and -independent T cell death is induced by nicotinamide adenine dinucleotide
J Immunol
2005
174
1971
1979

15699125


106.
Ferrari
D

Chiozzi
P

Falzoni
S



Extracellular ATP triggers IL-1β release by activating the purinergic P2Z receptor of human macrophages
J Immunol
1997
159
1451
1458

9233643


107.
Suzuki
T

Hide
I

Ido
K



7
 receptor-activated microglia
J Neurosci
2004
24
1
7

14715932


108.
Gu
B

Bendall
LJ

Wiley
JS


Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases
Blood
1998
92
946
951

9680363


109.
Labasi
JM

Petrushova
N

Donovan
C



7
 receptor alters leukocyte function and attenuates an inflammatory response
J Immunol
2002
168
6436
6445

12055263


110.
Idzko
M

Dichmann
S

Ferrari
D



Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors
Blood
2002
100
925
932

12130504


111.
Schmid-Antomarchi
H

Schmid-Alliana
A

Romey
G



2+
+
 channel
J Immunol
1997
159
6209
6215

9550424


112.
Hechler
B



1
/ApoE double knockout mice
Purinergic Signalling
2006
2
299

Hechler B et al (2006) Reduced atherosclerotic lesions in P2Y1/ApoE double knockout mice. Purinergic Signalling 2:299 

113.
Duhant
X

Schandené
L

Bruyns
C



Extracellular adenine nucleotides inhibit the activation of human CD4+ T lymphocytes
J Immunol
2002
169
15
21

12077223


114.
Kaufmann
A

nMusset
B

Limberg
SH



“Host tissue damage” signal ATP promotes non-directional migration and negatively regulates toll-like receptor signaling in human monocytes
J Biol Chem
2005
280
32459
32467

16030017


115.
Marteau
F

Gonzalez
NS

Communi
D



Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells
Blood
2005
106
3860
3866

16118322


116.
Amisten
S

Melander
O

Wihlborg
AK



11

Eur Heart J
2006
28
13
18

17135283


117.
Dawicki
DD

McGowan-Jordan
J

Bullard
S



Extracellular nucleotides stimulate leukocyte adherence to cultured pulmonary artery endothelial cells
Am J Physiol
1995
268
L666
L673

7733307


118.
Seiffert
K

Ding
W

Wagner
JA



ATPγS enhances the production of inflammatory mediators by a human dermal endothelial cell line via purinergic receptor signaling
J Invest Dermatol
2006
126
1017
1027

16410784


119.
Seye
CI

Yu
N

Jain
R



2
 nucleotide receptor mediates UTP-induced vascular cell adhesion molecule-1 expression in coronary artery endothelial cells
J Biol Chem
2003
278
24960
24965

12714597


120.
Seye
CI

Yu
N

González
FA



2
 nucleotide receptor mediates vascular cell adhesion molecule-1 expression through interaction with VEGF receptor-2 (KDR/Flk-1)
J Biol Chem
2004
279
35679
35686

15175347


121.
Seye
CI

Kong
Q

Erb
L



2
 nucleotide receptors mediate uridine 5’-triphosphate-induced intimal hyperplasia in collared rabbit carotid arteries
Circulation
2002
106
2720
2726

12438299


122.
Hart
MN

Heistad
DD

Brody
MJ


Effect of chronic hypertension and sympathetic denervation on wall/lumen ratio of cerebral vessels
Hypertension
1980
2
419
423

7399625


123.
Erlinge
D

Yoo
H

Edvinsson
L



Mitogenic effects of ATP on vascular smooth muscle cells vs. other growth factors and sympathetic cotransmitters
Am J Physiol
1993
265
H1089
H1097

7694483


124.
Wang
DJ

Huang
NN

Heppel
LA



Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cells
J Cell Physiol
1992
153
221
233

1358898


125.
Malam-Souley
R

Seye
C

Gadeau
AP



Nucleotide receptor P2u partially mediates ATP-induced cell cycle progression of aortic smooth muscle cells
J Cell Physiol
1996
166
57
65

8557776


126.
Erlinge
D

You
J

Wahlestedt
C



Characterisation of an ATP receptor mediating mitogenesis in vascular smooth muscle cells
Eur J Pharmacol
1995
289
135
149

7781705


127.
Hou
M

Harden
TK

Kuhn
CM



6
 receptors
Am J Physiol Heart Circ Physiol
2002
282
H784
H792

11788430


128.
Wilden
PA

Agazie
YM

Kaufman
R



ATP-stimulated smooth muscle cell proliferation requires independent ERK and PI3K signaling pathways
Am J Physiol
1998
275
H1209
H1215

9746468


129.
Sauzeau
V

Jeune
H

Cario-Toumaniantz
C



1
2
4
6
 receptors are coupled to Rho and Rho kinase activation in vascular myocytes
Am J Physiol Heart Circ Physiol
2000
278
H1751
H1761

10843869


130.
Miyagi
Y

Kobayashi
S

Ahmed
A



P2U purinergic activation leads to the cell cycle progression from the G1 to the S and M phases but not from the G0 to G1 phase in vascular smooth muscle cells in primary culture
Biochem Biophys Res Commun
1996
222
652
658

8670259


131.
Erlinge
D

Brunkwall
J

Edvinsson
L



Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP
Regul Pept
1994
50
259
265

8016410


132.
Erb
L

Liu
J

Ockerhausen
J



2
V
3
o
-mediated signal transduction
J Cell Biol
2001
153
491
501

11331301


133.
Robinson
WP

Douillet
CD

Milano
PM



ATP stimulates MMP-2 release from human aortic smooth muscle cells via JNK signaling pathway
Am J Physiol Heart Circ Physiol
2006
290
H1988
H1996

16361361


134.
Chaulet
H

Desgranges
C

Renault
MA



Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin
Circ Res
2001
89
772
778

11679406


135.
Koziak K et al (2006) Adenovirus-mediated over-expression of CD39 inhibits neointima formation in rat aorta. Purinergic Signalling 2:Addendum

136.
Imai
M

Takigami
K

Guckelberger
O



Modulation of nucleoside triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection
Mol Med
1999
5
743
752

10656876


137.
Pillois
X

Chaulet
H

Belloc
I



Nucleotide receptors involved in UTP-induced rat arterial smooth muscle cell migration
Circ Res
2002
90
678
681

11934835


138.
Ralevic
V

Belai
A

Burnstock
G


Effects of streptozotocin-diabetes on sympathetic nerve, endothelial and smooth muscle function in the rat mesenteric arterial bed
Eur J Pharmacol
1995
286
193
199

8605956


139.
Gür
S

Ozturk
B


Altered relaxant responses to adenosine and adenosine 5’-triphosphate in the corpus cavernosum from men and rats with diabetes
Pharmacology
2000
60
105
112

10657760


140.
Sprague
RS

Stephenson
AH

Bowles
EA



i
 in erythrocytes of humans with type 2 diabetes is associated with impairment of both cAMP generation and ATP release
Diabetes
2006
55
3588
3593

17130508


141.
Parodi
J

Flores
C

Aguayo
C



2
 purinoceptors in human umbilical vein endothelial cells
Circ Res
2002
90
570
577

11909821


142.
Hellman
B

Dansk
H

Grapengiesser
E


Pancreatic β-cells communicate via intermittent release of ATP
Am J Physiol Endocrinol Metab
2004
286
E759
E765

14722025


143.
Nilsson
J

Nilsson
NM

Chen
YW



High glucose activates nuclear factor of activated T cells in native vascular smooth muscle
Arterioscler Thromb Vasc Biol
2006
26
794
800

16469950


144.
Pacaud
P

Malam-Souley
R

Loirand
G



2+
i
 via different P2-receptor subtypes in freshly isolated and cultured aortic myocytes
Am J Physiol
1995
269
H30
H36

7631861


145.
Erlinge
D

Hou
M

Webb
TE



Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR
Biochem Biophys Res Commun
1998
248
864
870

9704019


146.
Hou
M

Möller
S

Edvinsson
L



2
 receptors in vascular smooth muscle cells
Biochem Biophys Res Commun
1999
258
648
652

10329439


147.
Hou
M

Möller
S

Edvinsson
L



2
 receptors and increased mitogenic responses to UTP and ATP
Arterioscler Thromb Vasc Biol
2000
20
2064
2069

10978250


148.
Seye
CI

Gadeau
AP

Daret
D



2
 purinoceptor in intimal lesions of the rat aorta
Arterioscler Thromb Vasc Biol
1997
17
3602
3610

9437211


149.
Shen
J

Seye
CI

Wang
M



2
 receptor in coronary artery smooth muscle cells
Mol Pharmacol
2004
66
1265
1274

15280443


150.
Hogarth
DK

Sandbo
N

Taurin
S



Dual role of PKA in phenotypic modulation of vascular smooth muscle cells by extracellular ATP
Am J Physiol Cell Physiol
2004
287
C449
C456

15238360


151.
Wang
L

Andersson
M

Karlsson
L



Increased mitogenic and decreased contractile P2 receptors in smooth muscle cells by shear stress in human vessels with intact endothelium
Arterioscler Thromb Vasc Biol
2003
23
1370
1376

12791671


152.
Daele
P

Coevorden
A

Roger
PP



Effects of adenine nucleotides on the proliferation of aortic endothelial cells
Circ Res
1992
70
82
90

1727689


153.
Kaczmarek
E

Erb
L

Koziak
K



Modulation of endothelial cell migration by extracellular nucleotides: involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways
Thromb Haemost
2005
93
735
742

15841322


154.
Gerasimovskaya
EV

Davie
NJ

Ahmad
S



Extracellular adenosine triphosphate: a potential regulator of vasa vasorum neovascularization in hypoxia-induced pulmonary vascular remodeling
Chest
2005
128
6 Suppl
608S
610S

16373860


155.
Eltzschig
HK

Ibla
JC

Furuta
GT


Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors
J Exp Med
2003
198
783
796

12939345


156.
Goepfert
C

Sundberg
C

Sévigny
J



Disordered cellular migration and angiogenesis in cd39-null mice
Circulation
2001
104
3109
3115

11748109


157.
Cario-Toumaniantz
C

Loirand
G

Ladoux
A



7
 receptor activation-induced contraction and lysis in human saphenous vein smooth muscle
Circ Res
1998
83
196
203

9686759


158.
Metcalfe
MJ

Baker
DM

Burnstock
G


Purinoceptor expression on keratinocytes reflects their function in the epidermis during chronic venous insufficiency
Arch Dermatol Res
2006
298
301
307

16967306


159.
Clemens
MG

Forrester
T


Appearance of adenosine triphosphate in the coronary sinus effluent from isolated working rat heart in response to hypoxia
J Physiol
1981
312
143
158

7264990


160.
Bogdanov
Y

Rubino
A

Burnstock
G


Characterisation of subtypes of the P2X and P2Y families of ATP receptors in the foetal human heart
Life Sci
1998
62
697
703

9489506


161.
Wihlborg
AK

Balogh
J

Wang
L



2
6
 receptors on cardiomyocytes and release of UTP in man during myocardial infarction
Circ Res
2006
98
970
976

16543499


162.
Danziger
RS

Raffaeli
S

Moreno-Sanchez
R



Extracellular ATP has a potent effect to enhance cytosolic calcium and contractility in single ventricular myocytes
Cell Calcium
1988
9
193
199

3191528


163.
Zheng
JS

Boluyt
MO

Long
X



Extracellular ATP inhibits adrenergic agonist-induced hypertrophy of neonatal cardiac myocytes
Circ Res
1996
78
525
535

8635209


164.
Podrasky
E

Xu
D

Liang
BT



A novel phospholipase C- and cAMP-independent positive inotropic mechanism via a P2 purinoceptor
Am J Physiol
1997
273
H2380
H2387

9374775


165.
Mei
Q

Liang
BT


P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts
Am J Physiol Heart Circ Physiol
2001
281
H334
H341

11406501


166.
Froldi
G

Pandolfo
L

Chinellato
A



Dual effect of ATP and UTP on rat atria: which types of receptors are involved?
Naunyn Schmiedebergs Arch Pharmacol
1994
349
381
386

8058110


167.
Scamps
F

Vassort
G


Pharmacological profile of the ATP-mediated increase in L-type calcium current amplitude and activation of a non-specific cationic current in rat ventricular cells
Br J Pharmacol
1994
113
982
986

7858894


168.
Vahlensieck
U

Bokník
P

Gombosová
I



Inotropic effects of diadenosine tetraphosphate (AP4A) in human and animal cardiac preparations
J Pharmacol Exp Ther
1999
288
805
813

9918592


169.
Balogh
J

Wihlborg
AK

Isackson
H



11
-like receptors
J Mol Cell Cardiol
2005
39
223
230

15893764


170.
Flitney
FW

Singh
J


Inotropic responses of the frog ventricle to adenosine triphosphate and related changes in endogenous cyclic nucleotides
J Physiol
1980
304
21
42

6255141


171.
Puceat
M

Bony
C

Jaconi
M



Specific activation of adenylyl cyclase V by a purinergic agonist
FEBS Lett
1998
431
189
194

9708900


172.
Communi
D

Govaerts
C

Parmentier
M



Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase
J Biol Chem
1997
272
31969
31973

9405388


173.
Communi
D

Robaye
B

Boeynaems
JM


11
 receptor
Br J Pharmacol
1999
128
1199
1206

10578132


174.
Zambon
AC

Hughes
RJ

Meszaros
JG



2
 receptor of MDCK cells: cloning, expression, and cell-specific signaling
Am J Physiol Renal Physiol
2000
279
F1045
F1052

11097622


175.
Hou
M

Malmsjö
M

Möller
S



1
2
-receptor mRNA levels in congestive heart failure
Life Sci
1999
65
1195
1206

10503935


176.
Froldi
G

Varani
K

Chinellato
A



P2X-purinoceptors in the heart: actions of ATP and UTP
Life Sci
1997
60
1419
1430

9126862


177.
Froldi
G

Ragazzi
E

Caparrotta
L



Do ATP and UTP involve cGMP in positive inotropism on rat atria?
Comp Biochem Physiol C Toxicol Pharmacol
2001
128
265
274

11239839


178.
Erlinge
D

Harnek
J

Heusden
C



Uridine triphosphate (UTP) is released during cardiac ischemia
Int J Cardiol
2005
100
427
433

15837087


179.
Borna
C

Lazarowski
E

Heusden
C



Resistance to aspirin is increased by ST–elevation myocardial infarction and correlates with adenosine diphosphate levels
Thromb J
2005
3
10

16045804


180.
Kittel
A

Kiss
AL

Müllner
N



Expression of NTPDase1 and caveolins in human cardiovascular disease
Histochem Cell Biol
2005
124
51
59

16028070


181.
Gunduz
D

Kasseckert
SA

Härtel
FV



Accumulation of extracellular ATP protects against acute reperfusion injury in rat heart endothelial cells
Cardiovasc Res
2006
71
764
773

16836989


182.
Pham
TM

Morris
JB

Arthur
JF



UTP but not ATP causes hypertrophic growth in neonatal rat cardiomyocytes
J Mol Cell Cardiol
2003
35
287
292

12676543


183.
Zheng
JS

Boluyt
MO

O’Neill
L



Extracellular ATP induces immediate-early gene expression but not cellular hypertrophy in neonatal cardiac myocytes
Circ Res
1994
74
1034
1041

8187273


184.
Morris
JB

Pham
TM

Kenney
B



UTP transactivates epidermal growth factor receptors and promotes cardiomyocyte hypertrophy despite inhibiting transcription of the hypertrophic marker gene, atrial natriuretic peptide
J Biol Chem
2004
279
8740
8746

14676212


185.
Yitzhaki
S

Shneyvays
V

Jacobson
KA



Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress
Biochem Pharmacol
2005
69
1215
1223

15794942


186.
Yitzhaki
S

Shainberg
A

Cheporko
Y



Uridine-5’-triphosphate (UTP) reduces infarct size and improves rat heart function after myocardial infarct
Biochem Pharmacol
2006
72
949
955

16939682


187.
Saini
HK

Shao
Q

Musat
S



Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction
Br J Pharmacol
2005
144
202
211

15665860


188.
Banfi
C

Ferrario
S

Vincenti
O



6
 in patients undergoing heart transplantation, interaction with TNFα and potential role in myocardial cell death
J Mol Cell Cardiol
2005
39
929
939

16242142


189.
Malmsjö
M

Bergdahl
A

Möller
S



1
-receptors in resistance arteries
Cardiovasc Res
1999
43
219
227

10536707


190.
Yang
A

Sonin
D

Jones
L



4
 receptors in heart failure: rescue of the calsequestrin overexpression model of cardiomyopathy
Am J Physiol Heart Circ Physiol
2004
287
H1096
H1103

15130891


191.
Horackova
M

Huang
MH

Armour
JA



Purinergic modulation of adult guinea pig cardiomyocytes in long term cultures and co-cultures with extracardiac or intrinsic cardiac neurones
Cardiovasc Res
1994
28
673
679

8025912


192.
Jiang
L

Bardini
M

Keogh
A



1
 receptors are closely associated with connexin 43 in human ventricular myocardium
Int J Cardiol
2005
98
291
297

15686781


193.
Gaarder
A

Jonsen
J

Laland
S



Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets
Nature
1961
192
531
532

13896038


194.
Daniel
JL

Dangelmaier
C

Jin
J



Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets
J Biol Chem
1998
273
2024
2029

9442039


195.
Jin
J

Kunapuli
SP


Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation
Proc Natl Acad Sci USA
1998
95
8070
8074

9653141


196.
Jin
J

Daniel
JL

Kunapuli
SP


1
 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets
J Biol Chem
1998
273
2030
2034

9442040


197.
Kunapuli
SP

Dorsam
RT

Kim
S



Platelet purinergic receptors
Curr Opin Pharmacol
2003
3
175
180

12681240


198.
Gachet
C

Hechler
B


The platelet P2 receptors in thrombosis
Semin Thromb Hemost
2005
31
162
167

15852219


199.
Foster
CJ

Prosser
DM

Agans
JM



Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs
J Clin Invest
2001
107
1591
1598

11413167


200.
Fabre
JE

Nguyen
M

Latour
A



1
-deficient mice
Nat Med
1999
5
1199
1202

10502826


201.
Leon
C

Alex
M

Klocke
A



Platelet ADP receptors contribute to the initiation of intravascular coagulation
Blood
2004
103
594
600

12969982


202.
Gachet
C


The platelet P2 receptors as molecular targets for old and new antiplatelet drugs
Pharmacol Ther
2005
108
180
192

15955565


203.
Leon
C

Hechler
B

Freund
M



1
 receptor-null mice
J Clin Invest
1999
104
1731
1737

10606627


204.
Mahaut-Smith
MP

Tolhurst
G

Evans
RJ


1
 receptors in platelet activation
Platelets
2004
15
131
144

15203715


205.
Birk
AV

Leno
E

Robertson
HD



Interaction between ATP and catecholamines in stimulation of platelet aggregation
Am J Physiol Heart Circ Physiol
2003
284
H619
H625

12388296


206.
Sévigny
J

Sundberg
C

Braun
N



Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation
Blood
2002
99
2801
2809

11929769


207.
Robson
SC

Kaczmarek
E

Siegel
JB



Loss of ATP diphosphohydrolase activity with endothelial cell activation
J Exp Med
1997
185
153
163

8996251


208.
Koyamada
N

Miyatake
T

Candinas
D



Apyrase administration prolongs discordant xenograft survival
Transplantation
1996
62
1739
1743

8990354


209.
Imai
M

Takigami
K

Guckelberger
O



Recombinant adenoviral mediated CD39 gene transfer prolongs cardiac xenograft survival
Transplantation
2000
70
864
870

11014639


210.
Mizumoto
N

Kumamoto
T

Robson
SC



CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness
Nat Med
2002
8
358
365

11927941


211.
Pearson
JD


The control of production and release of haemostatic factors in the endothelial cell
Baillieres Clin Haematol
1993
6
629
651

8025346


212.
Bouchie
JL

Chen
HC

Carney
R



P2Y receptor regulation of PAI-1 expression in vascular smooth muscle cells
Arterioscler Thromb Vasc Biol
2000
20
866
873

10712415


213.
CAPRIE Steering Committee

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events
Lancet
1996
348
1329
1339

8918275


214.
Mehta
SR

Yusuf
S

Peters
RJ



Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
Lancet
2001
358
527
533

11520521


215.
Payne
DA

Jones
CI

Hayes
PD



Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy
Circulation
2004
109
1476
1481

15007001



http://dx.doi.org/10.1007/s11302-007-9092-9





